Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
19.85
-0.65 (-3.17%)
Jan 27, 2026, 4:00 PM EST - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 6 analysts that cover Pacira BioSciences stock have a consensus rating of "Strong Buy" and an average price target of $35.33, which forecasts a 77.98% increase in the stock price over the next year. The lowest target is $24 and the highest is $65.
Price Target: $35.33 (+77.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 1 | 2 | 1 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +91.44% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +51.13% | Jan 9, 2026 |
| Barclays | Barclays | Hold Initiates $27 | Hold | Initiates | $27 | +36.02% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +91.44% | Nov 17, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +41.06% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
744.49M
from 700.97M
Increased by 6.21%
Revenue Next Year
806.02M
from 744.49M
Increased by 8.26%
EPS This Year
3.01
from -2.15
EPS Next Year
3.48
from 3.01
Increased by 15.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 769.3M | 848.5M | ||||
| Avg | 744.5M | 806.0M | ||||
| Low | 711.9M | 759.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.8% | 14.0% | ||||
| Avg | 6.2% | 8.3% | ||||
| Low | 1.6% | 2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.20 | 4.03 | ||||
| Avg | 3.01 | 3.48 | ||||
| Low | 2.81 | 2.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 33.7% | ||||
| Avg | - | 15.3% | ||||
| Low | - | -1.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.